Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Henry Meds vs MyStart Health

Henry Meds
Graded #46

Higher grade

vs+10.200000000000003
MyStart Health
Graded #168

Lower grade

The verdict

Henry Meds takes it — 77.3/100 to 67.1/100.

Henry Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A flat-fee compounded pioneer — simple, but priced at the higher end of the board now.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHenry Meds +24
72
48
Dose & formulationMyStart Health +3
80
83
Clinical oversightMyStart Health +4
80
84
Labs & monitoringHenry Meds +12
78
66
FulfillmentEven
78
78
Contract termsHenry Meds +47
78
31
Henry Meds · left barMyStart Health · right bar

The numbers

MetricHenry MedsMyStart Health
WeighScore77.3/10067.1/100
GradeC+C
Scorecard rank#46#168
Semaglutide$249/mo$299/mo (all doses, compounded)
Tirzepatide$349/mo$299/mo (all doses, compounded)
CoverageMulti-stateCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Henry Meds

Graded #46 · C+

Strengths

  • Simple flat-fee model
  • Established brand
  • Both molecules

Where it loses points

  • Higher pricing than newer entrants
  • Compounded only
MyStart Health

Graded #168 · C

Strengths

  • Price Lock Guarantee — your $299 base rate doesn't rise as your dose escalates
  • Fast onboarding: roughly 5-minute intake, 24-hour prescription turnaround, 2–4 day shipping
  • 24/7 care team access with unlimited clinician messaging included
  • LegitScript certified
  • Clear Section 503A compounding disclosure on every landing page

Where it loses points

  • Not BBB accredited — C+ rating with 10 complaints, mostly shipping delays and support access
  • Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
  • Markets oral tirzepatide, but no FDA-approved oral tirzepatide exists
  • Very new company (incorporated May 2024) with a limited track record
  • Pharmacy partners not named, so 503A compliance can't be independently verified

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard